Oncotelic Targets Brain Delivery with Nose-to-Brain Platform

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself within a growing push to overcome one of modern medicine’s most persistent challenges: delivering therapeutics effectively across the blood-brain barrier. Through its proprietary intranasal nose-to-brain delivery platform, the company is pursuing targeted central nervous system applications spanning Alzheimer’s disease and biodefense, reflecting broader industry recognition that delivery technology may be as critical as drug discovery itself. Oncotelic is part of an innovative therapeutic landscape that includes Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).

As the global burden of neurodegenerative disease rises and biodefense preparedness becomes a growing strategic priority, advanced CNS delivery platforms are attracting increased attention as potential solutions to longstanding treatment limitations. Oncotelic’s platform-based approach is designed to bypass traditional delivery barriers and enable rapid therapeutic access to the brain, positioning the company within an evolving biopharma sector increasingly focused on scalable, targeted and adaptable treatment technologies. The company’s pipeline includes oncology and immunotherapy products, and it leverages its proprietary AI-enabled PDAOAI platform to support research and biomarker discovery. Oncotelic also holds a 45% interest in GMP Bio, a joint venture advancing complementary therapeutic candidates.

Oncotelic is part of the Dynamic Brand Portfolio @ IBN, which includes InvestorWire, a specialized communications platform for press release syndication. The full press release is available at https://ibn.fm/BVipB.